LinkDoc has collaborated with over 600 departments from more than 300 oncology centers in China, positioning itself as a dominant player in oncology-focused real-world data. The company's main businesses include pharmaceutical Real World Study (RWS), patient health management services, and patient recruitment services, focusing on major disease areas represented by oncology and rare diseases. As of April 2024, LinkDoc Technology was valued at 7.1 billion yuan and ranked 1118th on the Hurun Global Unicorn List.
Cyborg Score Rationale
LinkDoc holds a defensible unicorn position with $253.02M in total funding and $143.7M in annual revenue as of 2025. The company's first-mover advantage in China's oncology data space and partnerships with top healthcare institutions provide strong competitive moat. However, regulatory risks from Beijing's crackdown on overseas listings and market concentration in China limit upside potential.
Top Insights
LinkDoc is one of the earliest medical technology companies deeply involved in medical big data governance and application, providing one-stop big data solutions for patients and industry stakeholders including life science companies, medical institutions, insurance organizations, and regulatory bodies
The company has developed proprietary machine learning and natural language processing mechanisms to structure millions of clinical EMR records into research-grade data
Major investors include Alibaba Health, China Broadband Capital, Youshan Capital, China Capital Investment Group, and China Investment
LinkDoc shelved U.S. IPO plans following China's crackdown on overseas listings by domestic firms, with future listing dependent on regulatory and market conditions improving
Named Competitors
Medidata — Clinical data platform for drug development and real-world evidence
Verily — Life sciences data and technology platform
IQVIA — Healthcare data, technology and research services
Recent Developments
(April 2024) Included in 2024 Hurun Global Unicorn List with valuation of 7.1 billion yuan
(2025) Annual revenue reached $143.7M
U.S. IPO plans halted due to China's regulatory restrictions on overseas listings
Open the full interactive LinkDoc Technology report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.